VIVUS, Inc. (VVUS)
(Delayed Data from NSDQ)
$3.73 USD
+0.03 (0.81%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.83 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.73 USD
+0.03 (0.81%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.83 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
VIVUS (VVUS) Loss Narrower than Expected, Revenues Up Y/Y
by Zacks Equity Research
VIVUS Inc. (VVUS) reported a loss of 1 cent per share in the first quarter of 2017, which was narrower than a loss of 12 cents in the year-ago period as well as the Zacks Consensus Estimate of a loss of 13 cents
VIVUS (VVUS) Down 14.1% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
VIVUS (VVUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
VIVUS to Regain Commercial Rights for Stendra from Sanofi
by Zacks Equity Research
VIVUS, Inc. (VVUS) recently announced an agreement with Sanofi to reacquire the commercial rights to its erectile dysfunction drug, Stendrain Africa, the Middle East, Turkey and the Commonwealth of Independent States, including Russia.
Orexigen Inks Commercialization Deal for Contrave, Stock Up
by Zacks Equity Research
Orexigen Therapeutics, Inc.'s (OREX) announced that it has entered into a commercialization and distributorship agreement with Italian pharmaceutical company, Bruno Farmaceutici, for its obesity drug, Contrave.
VIVUS (VVUS) Beats on Q4 Earnings, Revenues Increase Y/Y
by Zacks Equity Research
VIVUS Inc. (VVUS) reported earnings of 54 cents per share in the fourth quarter of 2016 as against a loss of 12 cents in the year-ago period
VIVUS Licenses Rights to PAH Drugs from Selten Pharma
by Zacks Equity Research
VIVUS, Inc. (VVUS) acquired exclusive global rights to develop and commercialize pulmonary arterial hypertension (PAH) drugs, tacrolimus and ascomycin from private biotech company, Selten Pharma, Inc.
VIVUS (VVUS): Will Qsymia & Stendra Sales Improve in 2017?
by Zacks Equity Research
On Jan 3, we issued an updated report on VIVUS, Inc. (VVUS).
4 Biotech Stocks with Bright Prospects in 2017
by Zacks Equity Research
Even as the drug pricing issue continues to plague the biotech sector, investors should find it safe to bet on these top-ranked biotech stocks that also have superb Style Score as markets roll into 2017.
5 Top Performing Biotechnology Stocks of November
by Zacks Equity Research
November was a great month for pharma/biotech stocks after a rather difficult year when the industry struggled with media and political focus on high drug prices.